Ashley E. Ross
YOU?
Author Swipe
View article: Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey‐Holden Prostate Cancer Academy Meeting
Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey‐Holden Prostate Cancer Academy Meeting Open
Introduction The 12th Annual 2025 Coffey—Holden Prostate Cancer Academy (CHPCA) Meeting, “Deciphering Resistance: Beyond the Androgen Paradigm,” was held at the University of California, Los Angeles (UCLA), Luskin Conference Center, in Los…
View article: Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP) Open
Patients with prostate cancer treated with radiotherapy (RT) or radical prostatectomy (RP) as primary therapy may develop biochemical recurrence (BCR), which requires effective treatment to delay disease progression. The ARASTEP study (NCT…
View article: Contemporary assessment of diagnostic performance and histologic concordance of renal mass biopsy with surgical pathology
Contemporary assessment of diagnostic performance and histologic concordance of renal mass biopsy with surgical pathology Open
Background Improvements in imaging and technique have led to a greater role for renal mass biopsy (RMB) to risk‐stratify localized renal masses. We sought to assess the contemporary diagnostic accuracy of RMB for identifying renal cell car…
View article: Effect of prior HoLEP procedure on multiparametric MRI accuracy in detection of prostate cancer
Effect of prior HoLEP procedure on multiparametric MRI accuracy in detection of prostate cancer Open
Objectives The objective of this study is to evaluate whether prior Holmium laser enucleation of the prostate (HoLEP) affects the diagnostic accuracy of multiparametric prostate MRI (mpMRI) with PI‐RADS scoring for detecting clinically sig…
View article: Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide
Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide Open
Objectives To evaluate the longitudinal transcriptomic changes that occurred over time in patients from the ENACT trial (ClinicalTrials.gov identifier: NCT02799745). ENACT evaluated patients with low‐ or intermediate‐risk prostate cancer, …
View article: Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance
Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance Open
Background Genomic biomarkers offer opportunities to improve risk stratification for patients with prostate cancer. We performed a transcriptomic profile of active surveillance (AS)‐eligible patients who underwent radical prostatectomy (RP…
Germline Testing for Prostate Cancer Patients: Evidence‐Based Evaluation of Genes Recommended by NCCN Guidelines Open
Background Approximately 50% of prostate cancer (PCa) patients meet the National Comprehensive Cancer Network (NCCN) guidelines for germline testing at diagnosis. However, the selection of genes for testing, their supporting evidence, and …
View article: PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer Open
Objectives To describe PSMA PET/CT characteristics of patients with high‐risk BCR. Subjects/patients and methods This was a retrospective analysis of patients with high‐risk BCR prostate cancer (PSA ≥ 2 ng/ml above nadir after radiation th…
View article: Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non–Digital Rectal Examination Urine
Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non–Digital Rectal Examination Urine Open
Using first-catch urine, MPS2 meaningfully improved the proportion of biopsies avoided relative to PCPTrc while maintaining highly sensitive detection of GG ≥ 2 cancer. Non-DRE testing provides a convenient, objective, and highly accurate …
View article: Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients Open
Darolutamide plus androgen-deprivation therapy (ADT) with docetaxel is one of the standards of care for metastatic hormone-sensitive prostate cancer (mHSPC), based on the phase III ARASENS study. To provide the option to use darolutamide w…
View article: Negative Predictive Value of a Prostate MRI in Black Men: Implications for Biopsy Decision-Making
Negative Predictive Value of a Prostate MRI in Black Men: Implications for Biopsy Decision-Making Open
PIRADS < 3 has a lower NPV and sensitivity in Black men. For negative prostate MRIs, PSAD ≥ 0.09 may be a better threshold for safe biopsy deferral in Black men to maintain a ≥ 90% sensitivity.
Detection of MRI‐Invisible Disease Using PSMA PET/CT in a Patient Considering Focal Therapy Open
Patient selection for focal therapy (FT) of prostate cancer requires the assessment of MRI and biopsy results. However, there is currently little guidance for the utility of PSMA PET/CT in FT planning. We describe the case of a man origina…
View article: Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now Open
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for man…
View article: Utilization of cardiopulmonary bypass at radical nephrectomy for renal cell carcinoma with tumour thrombus
Utilization of cardiopulmonary bypass at radical nephrectomy for renal cell carcinoma with tumour thrombus Open
Objectives The objective of this study is to evaluate preoperative factors associated with cardiopulmonary bypass (CPB) utilization and outcomes for patients with renal cell carcinoma (RCC) and tumour thrombus (TT). Radical nephrectomy wit…
SpaceOAR Persistence on MRI at 59 Weeks Postplacement in a Patient With Stage IV CKD Open
External beam radiation therapy is commonly used to treat prostate cancer, and gel spacers such as SpaceOAR Hydrogel (Boston Scientific, Marlborough, MA) are approved to limit local rectal radiation toxicity. SpaceOAR is usually reabsorbed…
View article: Development and prospective validation of a prostate cancer detection, grading, and workflow optimization system at an academic medical center
Development and prospective validation of a prostate cancer detection, grading, and workflow optimization system at an academic medical center Open
Artificial intelligence may assist healthcare systems in meeting increasing demand for pathology services while maintaining diagnostic quality and reducing turnaround time and costs. We aimed to investigate the performance of an institutio…
View article: Treatment Modalities and Risks of Complication for Patients With Localized Renal Cell Carcinoma Aged 75 and Older
Treatment Modalities and Risks of Complication for Patients With Localized Renal Cell Carcinoma Aged 75 and Older Open
Background and Objectives Partial (PN)/radical (RN) nephrectomy is the standard treatment for localized renal‐cell carcinoma (RCC). The potential risks of these procedures are concerns for the elderly. We evaluated perioperative outcomes/s…
View article: Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system
Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system Open
INTRODUCTION: The Society of Nuclear Medicine and Molecular Imaging (SNMMI) provides appropriate use criteria (AUC) for prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) which include guidanc…
View article: Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial
Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial Open
This randomized clinical trial compares the effect of transperineal vs transrectal prostate biopsy on infection rates after biopsy.
View article: Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate Open
Background To evaluate contemporary preoperative risk factors and subsequent postoperative management of incidental prostate cancer (iPCa) and incidental clinically significant prostate cancer (icsPCa, Grade Group [GG] ≥ 2 PCa). Methods A …
View article: Utility of dynamic contrast enhancement for clinically significant prostate cancer detection
Utility of dynamic contrast enhancement for clinically significant prostate cancer detection Open
Objective This study aimed to evaluate the association of dynamic contrast enhancement (DCE) with clinically significant prostate cancer (csPCa, Gleason Grade Group ≥2) and compare biparametric magnetic resonance imaging (bpMRI) and multip…
View article: Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting Open
This study looked at the use of the Decipher genomic classifier, a test used to help understand the aggressiveness of a patient's prostate cancer. Looking at the results of 58 935 participants who underwent testing, we found that the Decip…
View article: Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study Open
PURPOSE To characterize the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)–based metastatic spread. MATERIALS AND METHODS We i…
View article: Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage Open
Importance Although tissue-based gene expression testing has become widely used for prostate cancer risk stratification, its prognostic performance in the setting of clinical care is not well understood. Objective To develop a linkage betw…
View article: Prostate MRI and Clinicopathologic Risk Calculator to Predict Laterality of Extraprostatic Extension at Radical Prostatectomy
Prostate MRI and Clinicopathologic Risk Calculator to Predict Laterality of Extraprostatic Extension at Radical Prostatectomy Open
Background Traditional nomograms can inform the presence of extraprostatic extension (EPE) but not laterality, which remains important for surgical planning, and have not fully incorporated multiparametric MRI data. We evaluated predictors…
Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate Cancer Open
Once fully validated, this de novo measure may be used in clinical studies and clinical practice to assess hormone therapy-related symptoms and impacts, enabling physicians to identify timely and appropriate interventions.
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis Open
BACKGROUND: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. OBJECTIVE: We evaluated the clinical activity and safety of neoadjuvant cisplatin plus gem…
View article: Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era
Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era Open
Background Multiparametric prostate MRI (mpMRI) is being increasingly adopted for work-up of prostate cancer. For patients selected to omit biopsy, we identified factors associated with repeat MRI, eventual prostate biopsy, and subsequent …